September 2024

Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT® this year, with four indications overall RARITAN, N.J., Sept. 19, 2024 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Dr

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: